Cargando…
MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma
Soft-tissue sarcoma (STS) is represented by a heterogeneous group of rare malignancies with various molecular oncogenesis. Therapies targeting DNA repair pathways in STS have achieved minimal progress, potentially due to the lack of molecular biomarker(s) beyond the histology subtype. In this report...
Autores principales: | Liu, Qi, Bao, Qiyuan, Xu, Yiqi, Fu, Yucheng, Jin, Zhijian, Wang, Jun, Zhang, Weibin, Shen, Yuhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222794/ https://www.ncbi.nlm.nih.gov/pubmed/34178990 http://dx.doi.org/10.3389/fcell.2021.666376 |
Ejemplares similares
-
Development and Validation of a Hypoxia-Associated Prognostic Signature Related to Osteosarcoma Metastasis and Immune Infiltration
por: Fu, Yucheng, et al.
Publicado: (2021) -
Multi-Omics Analysis of MCM2 as a Promising Biomarker in Pan-Cancer
por: Yuan, Jing, et al.
Publicado: (2022) -
The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling
por: Pankova, Valeriya, et al.
Publicado: (2021) -
MCM3AP-AS1: An Indispensable Cancer-Related LncRNA
por: Yu, Xiao, et al.
Publicado: (2021) -
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer
por: Zhang, Lin-lin, et al.
Publicado: (2021)